MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202641075297 A) filed by Dr. Kondapuram Parameshwar; Dr. Raghavendra Kumar Gunda; Dr. Sagar Pamu; Dr. Sayyad Mustak; Ms. Adla Bindu Sree; Mr. Agiru Balakrishna; Mr. Akke Jayendra; Ms. Akula Keerthana; and Ms. Akula Ruchitha on June 18, 2026, for A Pharmaceutical Cubosomal Gel Composition Comprising 5-Fluorouracil For Transdermal Drug Delivery And Method Of Preparation Thereof.
Inventors include Dr. Kondapuram Parameshwar; Dr. Raghavendra Kumar Gunda; Dr. Sagar Pamu; Dr. Sayyad Mustak; Ms. Adla Bindu Sree; Mr. Agiru Balakrishna; Mr. Akke Jayendra; Ms. Akula Keerthana; and Ms. Akula Ruchitha.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: The present invention relates to a pharmaceutical cubosomal gel composition for transdermal delivery of 5-fluorouracil (5-FU) and a method of preparation thereof. The invention pertains to lipid-based nanostructured drug delivery systems designed to overcome limitations associated with conventional administration of 5-fluorouracil, including low bioavailability, rapid metabolic degradation, and systemic toxicity.The composition comprises glyceryl monooleate (GMO) as a lipid phase, non-ionic surfactants such as Poloxamer 407, Tween 80, and soya lecithin, and an aqueous phase, wherein 5-fluorouracil is encapsulated within cubosome nanostructures exhibiting a bicontinuous cubic liquid crystalline phase. The cubosomal dispersion is incorporated into a pharmaceutically acceptable gel base to enhance topical application and improve skin residence time.The method of preparation involves melting the lipid phase, incorporation of 5-fluorouracil and surfactants, hydration under homogenization or sonication to form cubosomes, followed by dispersion into a gel matrix. The formulation provides controlled drug release and enhanced permeation of 5-fluorouracil through the skin. The composition is useful for topical delivery in the treatment of skin cancer and related neoplastic conditions.
Disclaimer: Curated by HT Syndication.
